This protocol addresses parotid gland cancer presenting as adenoid cystic carcinoma (ACC) in the context of metastatic disease. Adenoid cystic carcinoma is a distinct histologic subtype that can exhibit an indolent but persistent clinical course, and the presence of metastatic spread shapes the treatment strategy significantly.
Patients presenting with metastatic disease may be evaluated for further treatments. In selected cases — particularly where tumour biology is indolent — local ablative treatment is among the approaches that may be considered to address disease progression. The complete structured regimen, including the full range of options and patient selection criteria, is available in the protocol.
DOI: 10.1200/JCO.21.00449
Patients presenting with metastatic disease may be evaluated for further treatments such as local ablative treatments or systemic therapy.
In the setting of ACC and/or low-grade tumors with indolent biology with limited metastases (ie, # 5 metastases), local ablative treatments such as surgery (metastatectomy) or stereotactic body radiation therapy may be offered to delay local disease progression.